Skip to content
Subscriber Only
Technology
Prognosis

Gilead Gets an Upgrade With Street Mulling Remdesivir Profit

Gilead headquarters in Foster City, California.

Gilead headquarters in Foster City, California.

Photographer: David Paul Morris/Bloomberg
Updated on

The latest look at Gilead Sciences Inc.’s treatment for Covid-19 has Wall Street analysts contemplating profit, some for the first time.

After initial donations run out, Gilead could be making commercial revenue from remdesivir as soon as the third quarter, SunTrust analyst Robyn Karnauskas said after speaking to management including the biotech’s chief financial officer.